secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aprea Therapeutics, Inc. (APRE)
CIK:        0001781983
Form:       8-K
Filed at:   2025-02-05T23:59:59+00:00
Accession:  0001558370-25-000641
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aprea Therapeutics updates patent portfolio for ATR and WEE1 inhibitor programs
-------------------------------------------------------------------------------

- ATR inhibitor program: 4 granted US patents, 1 pending US application, 1 provisional; 19 granted non-US patents, 16 pending non-US applications.
- Granted patents expire 2035-2037; pending applications may extend exclusivity to 2044.
- Lead ATR inhibitor ATRN-119 in Phase 1 ABOYA-119 trial for solid tumors with DDR mutations.
- WEE1 inhibitor program: 1 pending US application, 12 pending non-US applications; if granted, expire 2043.
- Lead WEE1 inhibitor APR-1051 in Phase 1 ACESOT-1051 trial for advanced/metastatic solid tumors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781983/000155837025000641/0001558370-25-000641-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781983/000155837025000641/apre-20250205x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-000641

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer